<DOC>
	<DOC>NCT00546728</DOC>
	<brief_summary>The purpose of this study is to compare the effects of exenatide versus metformin on vascular health with chronic (3-month) therapy and during a 2-hour period following a meal in patients with pre-diabetes. It is predicted that exenatide will improve vascular health to a greater degree compared to metformin.</brief_summary>
	<brief_title>The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Greater than or equal to 18 years old Impaired glucose tolerance: 2hr oral glucose tolerance test (OGTT) plasma glucose &gt;140 mg/dL OR impaired fasting glucose: fasting glucose &gt; or = 100 mg/dL OR elevated glycosylated hemoglobin: Hemoglobin A1c &gt; or = 5.7% Abdominal obesity: waist circumference &gt;102 cm (men) and &gt;88 cm (women) Stable cardiovascular medication regimen (or other medications known to affect endothelial function) at least 1 month prior to enrollment and throughout the study Type 2 diabetes Current use of glycemic control medications within one month of randomization Fasting glucose &gt;126 mg/dL Current use of weight loss medication Previous weight loss surgery History of severe gastrointestinal disease Standard clinical contraindications to exenatide or metformin therapy Unstable angina Heart failure Stroke or coronary artery bypass graft within 3 months of screening Women who are currently pregnant or planning to become pregnant Breastfeeding women Clinically significant liver disease Creatinine &gt; 1.5 mg/dL Hepatic function greater than 3 times upper limit of normal Patients who are mentally incompetent and cannot sign a Patient Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>